4.5 Article

Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease

Journal

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
Volume 2, Issue 1, Pages 30-37

Publisher

SAGE PUBLICATIONS INC
DOI: 10.1177/2050640613518201

Keywords

Calprotectin; Crohn's disease; diagnosis; follow up; inflammatory bowel disease; ulcerative colitis

Ask authors/readers for more resources

Background and objectives: Faecal calprotectin is a valuable noninvasive marker for inflammatory bowel disease (IBD). The aim of our study was to determine the correlation between six different calprotectin assays and compare their performance for diagnosis and follow up of IBD. Methods: Thirty-one patients with suspected IBD and 31 patients in follow up were included. We determined calprotectin by means of three rapid immmunochromatographic tests, two enzyme-linked immunosorbent assays, and one automated fluoroimmunoassay. Results were correlated with endoscopic and histological findings. Results: Although all methods correlated significantly, slopes and intercepts differed extensively, with up to 5-fold quantitative differences between assays. Sensitivity and specificity for diagnosis of IBD were 82-83 and 84-89%, respectively. For follow up, sensitivity in detecting mild ulcerative colitis was 71-100%. In moderate-to-severe ulcerative colitis, sensitivity was 100% for all assays. Specificity was 67-86% in both subgroups. In Crohn's disease, only moderate-to-severe disease could be differentiated from remission, with sensitivity 83-86% and specificity 75% for all tests. Conclusions: All calprotectin assays showed comparable clinical performance for diagnosis of IBD. For follow up, performance was acceptable, except for mild Crohn's disease. Because of the large quantitative differences, further efforts are needed to standardize calprotectin assays.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Obstetrics & Gynecology

Added prognostic value of Doppler ultrasound for adverse perinatal outcomes: A pooled analysis of three cohort studies

Madeline F. Flanagan, Charlotte A. Vollgraff Heidweiller-Schreurs, Wentao Li, Wessel Ganzevoort, Marjon A. de Boer, Alicia Vazquez-Sarandeses, Ozhan M. Turan, Patrick M. Bossuyt, Ben W. J. Mol, Daniel L. Rolnik

Summary: The study aimed to investigate the prognostic value of different Doppler ultrasound measurements for adverse perinatal outcomes. The results showed that umbilical artery pulsatility index added prognostic value for adverse perinatal outcomes, while other Doppler ultrasound measurements did not further improve prognostic performance.

AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY (2023)

Article Respiratory System

Ultra-low-dose CT versus chest X-ray for patients suspected of pulmonary disease at the emergency department: a multicentre randomised clinical trial

Inge A. H. van den Berk, Maadrika M. N. P. Kanglie, Tjitske S. R. van Engelen, Josje Altenburg, Jouke T. Annema, Ludo F. M. Beenen, Bart Boerrigter, Marije K. Bomers, Paul Bresser, Elvin Eryigit, Maarten Groenink, Suzanne M. R. Hochheimer, Frits Holleman, Jos A. J. Kooter, Ramon B. van Loon, Mitran Keijzers, Ivo van der Lee, Paul Luijendijk, Lilian J. Meijboom, Saskia Middeldorp, Laura J. Schijf, Robin Soetekouw, Ralf W. Sprengers, Alexander D. Montauban van Swijndregt, Wouter de Monye, Milan L. Ridderikhof, Michiel M. Winter, Shandra Bipat, Marcel G. W. Dijkgraaf, Patrick M. M. Bossuyt, Jan M. Prins, Jaap Stoker

Summary: Replacing chest X-ray with ultra-low-dose chest CT (ULDCT) in the diagnostic work-up of patients suspected of non-traumatic pulmonary disease at the emergency department has similar effects on short-term functional health, hospital admissions, and length of stay. However, more incidental findings were found in the ULDCT group.

THORAX (2023)

Article Gastroenterology & Hepatology

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Edouard Louis, Matthieu Resche-Rigon, David Laharie, Jack Satsangi, Nik Ding, Britta Siegmund, Geert D'Haens, Laurence Picon, Peter Bossuyt, Lucine Vuitton, Peter Irving, Stephanie Viennot, Christopher A. Lamb, Richard Pollok, Filip Baert, Maria Nachury, Mathurin Fumery, Cyrielle Gilletta, Sven Almer, Shomron Ben-Horin, Yoram Bouhnik, Jean-Frederic Colombel, Erik Hertervig

Summary: This study aimed to compare the relapse rate and time in remission over 2 years between patients continuing combination therapy, stopping infliximab, or stopping immunosuppressant therapy for Crohn's disease. The results showed that stopping infliximab had a higher relapse rate compared to stopping immunosuppressant therapy, suggesting that stopping immunosuppressant therapy may be a preferable strategy for treatment de-escalation.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

Review Health Care Sciences & Services

MASTRO I: Meta-Analysis and Systematic Review of thrombectomy stent retriever outcomes: comparing functional, safety and recanalization outcomes between EmboTrap, Solitaire and Trevo in acute ischemic stroke

Osama Zaidat, Shelly Ikeme, Sunil A. Sheth, Shinichi Yoshimura, Xin-guang Yang, Waleed Brinjikji, David F. Kallmes, Patrick Brouwer, John Pederson, Ranita Tarchand, Annie Steffenson, Kevin M. Kallmes, Jillienne Touchette, Tommy Andersson

Summary: A systematic review/meta-analysis compared three stent-retrievers (EmboTrap, Solitaire, and Trevo) and found that EmboTrap may be associated with significantly improved functional outcomes compared to Solitaire and Trevo. EmboTrap and Trevo may also have significantly lower rates of symptomatic intracranial hemorrhage and mortality compared to Solitaire. However, there were no significant differences in recanalization and embolization to new territory rates. Further studies comparing different stent-retriever devices are needed to confirm these findings.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2023)

Meeting Abstract Gastroenterology & Hepatology

Introducing video consultations as part of an IBD tight monitoring care pathway: interim results of the INTERACTION project

E. Hoefkens, N. Lembrechts, P. Bossuyt, L. Pouillon

JOURNAL OF CROHNS & COLITIS (2023)

Meeting Abstract Gastroenterology & Hepatology

Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis

V. Jairath, G. Zou, Z. Wang, S. Adsul, J. F. Colombel, G. R. D'Haens, M. Freire, G. W. Moran, L. Peyrin-Biroulet, W. J. Sandborn, S. Sebastian, S. Travis, S. Vermeire, G. Radulescu, J. Sigler, S. Mcfarlane, N. Arya, M. Beaton, P. Bossuyt, D. Green, W. Harlan, M. Horynski, M. Klopocka, R. Petroniene, M. S. Silverberg, L. Wolanski, B. G. Feagan

JOURNAL OF CROHNS & COLITIS (2023)

Meeting Abstract Gastroenterology & Hepatology

Change in fatigue in patients with Ulcerative Colitis or Crohn's disease initiating vedolizumab or other biologic therapy: Data from Belgian registry patients

E. Louis, P. Bossuyt, A. Colard, P. Caenepeel, F. Baert, A. Hantson, G. Van Gassen, J. Zhou, S. Vermeire

JOURNAL OF CROHNS & COLITIS (2023)

Meeting Abstract Gastroenterology & Hepatology

Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn's Disease (CD): Results from a large multinational prospective observational study

E. Louis, S. Sebastien, B. Siegmund, P. Bossuyt, S. Danese, N. De Boer, E. Loftus, B. Moum, L. Peyrin-Biroulet, S. Schreiber, J. Zhou, J. Wernicke, E. Angellotti, C. Siegel

JOURNAL OF CROHNS & COLITIS (2023)

Meeting Abstract Gastroenterology & Hepatology

Biological Treatment Cycles in Crohn's Disease

N. Noor, P. Sousa, D. Bettenworth, F. Gomollon, T. Lobaton, P. Bossuyt, M. J. Casanova, N. Ding, G. Dragoni, F. Furfaro, P. van Rheenen, M. Chaparro, J. Gisbert, E. Louis, K. Papamichael

JOURNAL OF CROHNS & COLITIS (2023)

Meeting Abstract Gastroenterology & Hepatology

Clinical response over 24 weeks for initial and delayed responders to induction therapy with risankizumab in Crohn's disease: data from the ADVANCE and MOTIVATE studies

R. Panaccione, I. Dotan, M. Ferrante, S. Danese, P. Bossuyt, K. Kligys, E. Neimark, J. Zambrano, X. Liao, G. D'Haens

JOURNAL OF CROHNS & COLITIS (2023)

Meeting Abstract Gastroenterology & Hepatology

Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn's disease

J. Panes, E. Louis, P. Bossuyt, N. Joshi, W. J. Lee, A. Lacerda, V. Remple, S. Xuan, E. V. Loftus

JOURNAL OF CROHNS & COLITIS (2023)

Meeting Abstract Gastroenterology & Hepatology

Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn's disease

J. Panes, E. Louis, P. Bossuyt, N. Joshi, W. J. Lee, A. Lacerda, V. Remple, S. Xuan, E. V. Loftus

JOURNAL OF CROHNS & COLITIS (2023)

Meeting Abstract Gastroenterology & Hepatology

Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn's Disease and Ulcerative Colitis

L. Peyrin-Biroulet, P. Bossuyt, D. Bettenworth, E. V. Loftus, S. Anjie, G. D'Haens, M. Saruta, P. Arkkila, D. H. Kim, D. Choi, W. Reinisch

JOURNAL OF CROHNS & COLITIS (2023)

Meeting Abstract Rheumatology

A PROSPECTIVE DIAGNOSTIC ACCURACY STUDY OF MULTI-MODALITY TESTING IN PATIENTS SUSPECTED OF A TREATABLE IIM: THE ADAPT STUDY PROTOCOL

Renske G. Kamperman, Hannah A. W. Walter, Joost Raaphorst, Camiel Verhamme, Johannes H. T. M. Koelman, Wouter V. Potters, Robert Hemke, Frank F. Smithuis, Eleonora Aronica, Ester M. M. van Leeuwen, Paul A. Baars, Marianne de Visser, Ivo N. van Schaik, Patrick M. M. Bossuyt, Anneke J. van der Kooi

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2023)

Article Health Care Sciences & Services

Patient-centred outcomes of imaging tests: recommendations for patients, clinicians and researchers

Matthew J. Thompson, Monica Zigman Suchsland, Victoria Hardy, Danielle C. Lavallee, Sally Lord, Emily Beth Devine, Jeffrey G. Jarvik, Steven Findlay, Thomas A. Trikalinos, Fiona M. Walter, Roger Chou, Beverly B. Green, Karen J. Wernli, Annette L. Fitzpatrick, Patrick M. Bossuyt

Summary: Imaging tests are commonly used in healthcare, but concerns about their overuse have overshadowed their benefits in clinical decision-making. This study demonstrates the importance of considering patient-centered outcomes (PCOs) when evaluating the value of imaging tests. The PROD framework categorizes PCOs into four main domains and highlights the interplay between them and the factors that can modify them.

BMJ QUALITY & SAFETY (2023)

No Data Available